IT·Science News

FDA approves Lilly’s Foundayo, a weight-loss pill with no food or water rules

US regulators approved Eli Lilly’s orforglipron, sold as Foundayo, on Wednesday 1 April, the Associated Press reported in a story carried by CTV News. AP described it as a second daily oral medication to treat obesity and other weight-related conditions, granted under a speedy review.

Newsweek set out the trial data: in a study of more than 3,000 adults with obesity, the 36 mg dose produced an average loss of 11.2% of body weight, about 25 pounds, over more than 16 months, against 2.1% on placebo. Gastrointestinal side effects led 5% to 10% of participants on the drug to stop treatment, against nearly 3% on placebo. Insured patients with a company discount card pay from $25 a month; cash prices run from $149 to $349 depending on dose. Newsweek said shipments were expected to begin the following Monday.

“We do expect approvals yet this year in several major markets.” — David Ricks, Lilly CEO, via The Week

How each outlet framed it

• CTV News — the AP news line: a fast-track approval and a second pill option.
• Newsweek — the practical detail: a small-molecule pill taken “without dietary restrictions”, unlike oral Wegovy, plus the full price ladder.
• The Week — the race: citing Reuters, Lilly’s pill can be taken at any time, while the Wegovy pill must be taken first thing in the morning, 30 minutes before food, water or other medicines; it also noted India’s drug regulator stepping up checks on unauthorised GLP-1 sales.

Where the numbers differ: The Week cites weight loss of 12% to 15% in trials, while Newsweek reports 11.2% for the top dose in the main study.